Integrated Science III: Lecture 4

Fundamentals of Toxicokinetics and Xenobiotic Disposition

• Toxicokinetics Defined: Toxicokinetics is the quantitative study of the movement of xenobiotics (foreign chemical substances or toxicants) within the body over time. It encompasses the continuous, interrelated processes of absorption, distribution, tissue localization, biotransformation (metabolism), and excretion (ADME). It represents the toxicological extension of pharmacokinetics.

• Clinical and Practical Importance: Mastering toxicokinetics is critical in clinical toxicology for selecting, timing, and administering therapeutic interventions (e.g., chelation, urinary pH adjustment, or hemodialysis) in poisoned patients.

• Target Concentration Principle: For a xenobiotic to produce a toxic response, it must reach and maintain an adequate concentration at its specific intracellular or tissue target site for a sufficient duration.

• Fundamental Determinants of Toxicant Concentration: The local concentration of a toxicant at any anatomical target site and time point is governed by two core processes:

  • Translocation: The physical transport of toxicant molecules throughout body fluids and tissues.

  • Chemical Transformation: The chemical modification of the toxicant via biotransformation (metabolism) and elimination pathways that diminish active toxicant levels.

• Modes of Translocation:

  • Bulk Flow Transfer: Rapid, long-distance movement of toxicant quantities conveyed through the cardiovascular circulatory system (bloodstream and lymph).

  • Diffusional Transfer: Short-distance, molecule-by-molecule transport across microscopic cellular barriers and membrane boundaries.

• Anatomical Exposure Routes and Circulatory Pathways:

  • Primary Sites of Exposure: Ingestion (gastrointestinal tract), inhalation (lungs), intravenous (IV), intraperitoneal (IP), subcutaneous (SC), intramuscular (IM), and dermal (skin).

  • Hepatic First-Pass Entry: All ingested toxicants absorbed across the gastrointestinal mucosa enter the portal vein blood flow and pass directly through the liver before reaching systemic circulation.

  • Systemic Distribution and Excretion Independence: Once a toxicant enters systemic blood and lymph, it circulates to all peripheral organs and tissues (e.g., kidneys, lungs, soft tissues, bone, adipose fat). The route of excretion is independent of the initial route of exposure; for instance, inhaled or dermally absorbed toxicants can still undergo biliary excretion in feces or renal excretion in urine.

Mechanisms of Transmembrane Movement and Barrier Crossing

• Role of Non-Aqueous Barriers: Cell membranes present hydrophobic, lipid-rich barriers. To undergo diffusional transfer across these cell barriers, xenobiotic molecules must possess a degree of lipid solubility to enter the membrane, while retaining sufficient water solubility to dissolve in and exit into the surrounding aqueous intracellular or extracellular environment.

• Passive Transfer Mechanisms:

  • Simple Diffusion:

  • Represents the mechanism by which the vast majority of drugs and xenobiotics cross cell membranes.

  • Molecules move passively along a concentration gradient (from higher concentration to lower concentration).

  • Requires the drug to be present in an aqueous solution adjacent to the lipid membrane.

  • It is a non-saturable process that requires no protein carriers and consumes no cellular energy (ATP).

  • Dependent on four key physical variables: concentration gradient magnitude, lipid solubility/degree of ionization, membrane thickness, and molecular size/weight.

  • Gradient Maintenance: The concentration gradient driving diffusion across the membrane is maintained continuously as long as the molecule is cleared, bound, or chemically transformed upon reaching the opposite side.

  • Lipid/Water Partition Coefficient: Measures lipid solubility. It is calculated by shaking the substance in a immiscible biphasic system (lipid phase and water phase) and measuring the equilibrium ratio of drug concentration in the lipid phase versus the water phase:

$\text{Partition Coefficient} = \frac{[\text{Drug}]_{\text{lipid}}}{[\text{Drug}]_{\text{water}}}$

• Filtration:

  • Occurs across capillary endothelial walls through large intercellular pores (fenestrations).

  • Allows the passage of virtually all free (unbound) plasma solutes and molecules regardless of their lipid solubility or ionization state.

  • Driven by hydrostatic pressure (which forces fluid and solutes out of the capillary) and osmotic pressure (which draws fluid back in).

  • Process is limited by regional blood flow rate, but is non-saturable.

• Specialized Transport Mechanisms:

  • Facilitated Diffusion:

  • Utilizes a transmembrane carrier protein to transport large or poorly lipid-soluble polar molecules (such as amino acids, glucose, neurotransmitters, and metal ions) across membranes along their electrochemical gradient.

  • Does not consume cellular energy (ATP independent).

  • It is a saturable process due to the fixed, finite number of carrier proteins available in the membrane.

  • Types of Co-Transport Carriers:

    • Uniport: Transports a single solute molecule unidirectionally across the membrane.

    • Symport: Co-transports two distinct molecules or ions simultaneously in the same direction.

    • Antiport: Co-transports two distinct molecules or ions in opposite directions across the membrane.

• Active Transport:

  • Moves solute molecules against a concentration or electrochemical gradient.

  • Requires direct consumption of metabolic energy (such as ATP hydrolysis) and involves specialized transmembrane carrier proteins.

  • It is saturable and susceptible to competitive inhibition.

  • Examples include the renal tubular active secretion of organic weak acids (e.g., penicillin, uric acid) and weak bases (e.g., histamine), as well as the neuronal $\text{Na}^+/\text{K}^+$ ATPase pump ($3\,\text{Na}^+$ pumped out, $2\,\text{K}^+$ pumped in per ATP molecule hydrolyzed).

• Pinocytosis:

  • A vesicular transport mechanism involving the localized invagination of the cell plasma membrane to engulf extracellular fluid and suspended macromolecules into an intracellular vesicle.

  • Vesicles can release their contents intracellularly or undergo transcytosis to discharge contents on the opposite surface of the cell barrier.

  • Examples include intestinal uptake of Vitamin B12 complexed with intrinsic factor, and the transcytosis of large peptide macromolecules (such as insulin) across the blood-brain barrier.

• Summary of Membrane Transport Mechanisms:

  • Passive Diffusion: Direction along gradient; energy required: No; carrier required: No; saturable: No.

  • Facilitated Diffusion: Direction along gradient; energy required: No; carrier required: Yes; saturable: Yes.

  • Active Transport: Direction against gradient; energy required: Yes (ATP); carrier required: Yes; saturable: Yes.

Physicochemical and Physiological Factors Governing Absorption

• Definition of Absorption: The process by which a drug or toxicant enters the systemic circulation from its site of administration.

• Physicochemical Drug Factors:

  • Degree of Ionization: Non-ionized (uncharged) forms of weak acids and bases are lipid-soluble and diffuse across biological membranes rapidly. Highly ionized (charged) forms have low lipid solubility and are blocked by cell membranes.

  • Weak Acid Equilibrium: $\text{HA} \rightleftharpoons \text{H}^+ + \text{A}^-$ (where $\text{HA}$ is unionized and $\text{A}^-$ is ionized)

  • Weak Base Equilibrium: $\text{BOH} \rightleftharpoons \text{B}^+ + \text{OH}^-$ (where $\text{BOH}$ is unionized and $\text{B}^+$ is ionized)

  • Ion Trapping Demonstration - Aspirin ($p\text{K}_a = 3.5$, weak acid): When an oral dose of $100\,\text{mg}$ aspirin is present in the stomach at $\text{pH} = 2.0$, the acidic environment suppresses dissociation, yielding $99.9\,\text{mg}$ in the unionized form ($\text{UI}$) and $0.1\,\text{mg}$ in the ionized form ($\text{I}$). Because $99.9\%$ is unionized, aspirin is rapidly absorbed across the gastric mucosa. Upon entering blood plasma ($\text{pH} = 7.4$), the equilibrium shifts such that $99.9\%$ dissociates into the ionized form ($\text{I}$), trapping the salicylate in the vascular compartment.

- **Ion Trapping Demonstration - Strychnine** ($p\text{K}_a = 8.0$, weak base): In the stomach at $\text{pH} = 2.0$, excess protons drive the base into its ionized state ($\text{I}$), resulting in $99.9\,\text{mg}$ ionized and $0.1\,\text{mg}$ unionized per $100\,\text{mg}$ dose. Thus, strychnine undergoes minimal absorption in the stomach and passes into the duodenum, where alkaline neutralization enables unionization and absorption.

• Therapeutic Manipulation of Urinary pH (Ion Trapping in Excretion):

  • Alkalinization of Urine: Administering Sodium Bicarbonate ($\text{NaHCO}_3$) alkalinizes urine, causing weak acid toxicants (e.g., aspirin) to convert into their ionized form within renal tubules, blocking passive tubular reabsorption and accelerating renal elimination.

  • Acidification of Urine: Administering Ascorbic Acid (Vitamin C) or Ammonium Chloride ($\text{NH}_4\text{Cl}$) acidifies urine, causing weak base drugs (e.g., amphetamine) to convert into their ionized form, preventing tubular reabsorption and enhancing excretion.

• Degree of Solubility: A high lipid/water partition coefficient enhances transmembrane absorption rate.

• Chemical Nature and Valency: Inorganic iron formulations are absorbed more efficiently than organic iron compounds. Ferrous iron ($\text{Fe}^{2+}$) is absorbed far more effectively than ferric iron ($\text{Fe}^{3+}$). Co-administering Vitamin C reduces $\text{Fe}^{3+}$ to $\text{Fe}^{2+}$, increasing net gastrointestinal iron absorption.

  • Pharmaceutical Form: Aqueous drug solutions are absorbed faster and more completely than suspensions or solid tablets.

  • Patient Physiological Factors:

• Route of Administration Rate: $\text{IV (seconds)} > \text{Inhaled (seconds)} > \text{IM (minutes)} > \text{Oral (minutes to hours)} > \text{Dermal (hours)}$

  • Transdermal administration (e.g., topical patches) provides slow, continuous release over extended durations.

• Absorbing Surface Area and Vascularity: Absorption rate is directly proportional to surface area and blood perfusion. Intestinal absorption is superior to stomach absorption because the intestine possesses a vastly larger surface area and higher blood flow.

• Pathological State of Absorbing Surface: Gastrointestinal disorders such as atrophic gastritis or malabsorption syndromes reduce the overall rate and extent of drug absorption.

• Rate of General Circulation: In clinical shock, peripheral tissue perfusion drops sharply. Subcutaneous or oral drug delivery becomes ineffective, making direct intravenous (IV) administration necessary.

• Specific Physiological Co-factors and Drug Interactions:

  • Intrinsic factor secreted by the gastric mucosa is required for Vitamin B12 absorption in the lower ileum.

  • Adrenaline (epinephrine) causes localized vasoconstriction; when co-administered with topical or local anesthetics, it delays systemic drug absorption and prolongs local anesthesia.

Pharmacokinetic Parameters and the Plasma Level Curve

• Plasma Level Curve Overview: Plots the total drug/toxicant concentration in blood plasma over time following an extravascular single dose.

• Key Pharmacokinetic Metrics:

  • $C_{\max}$: The maximal (peak) plasma drug concentration achieved by a given dose.

  • $t_{\max}$: The exact time point at which $C_{\max}$ is reached.

  • Lag Time: The time delay between drug administration and the initial detectable appearance of the drug in systemic blood plasma.

  • Onset of Activity: The time elapsed from administration until the plasma drug concentration crosses the Minimum Effective Concentration (MEC) threshold.

  • Duration of Action: The total duration during which the plasma drug concentration remains equal to or above the MEC threshold.

  • Time to Peak: The total elapsed time from dosage administration to reaching $C_{\max}$.

Bioavailability and Bioequivalence

• Bioavailability ($F$) Defined: The exact fraction of an administered drug dose that reaches systemic circulation in an unchanged, biologically active form.

• Standard Values: Intravenous (IV) administration delivers the drug directly into blood vessels, yielding an absolute bioavailability of $100\%$ ($F = 1.0$).

• Mathematical Calculation of Oral Bioavailability: Calculated by comparing the Area Under the Plasma Concentration-Time Curve (AUC) following oral dosing against the AUC following an identical intravenous dose:

$\text{Oral Bioavailability (\%)} = \frac{\text{AUC}_{\text{oral}}}{\text{AUC}_{\text{IV}}} \times 100$

• Factors Affecting Extravascular Bioavailability: Extent of transmucosal absorption in the GI tract and the degree of presystemic hepatic first-pass metabolism.

• Bioequivalence Defined: Two distinct drug formulations containing the same active ingredient are bioequivalent if they demonstrate identical bioavailability profiles and matching absorption rates, resulting in overlapping plasma concentration-time curves (e.g., brand-name drug versus generic equivalent).

Drug Distribution and Body Fluid Compartments

• Distribution Defined: The movement and reversible transfer of a drug or toxicant from the central intravascular compartment (blood) into peripheral tissue compartments.

• Governing Factors: Distribution depends on lipid solubility, ionization state, molecular size, plasma protein binding, regional organ blood flow rates, and special physiological barriers.

• Anatomical Body Fluid Compartments (based on a standard $70\,\text{kg}$ adult subject):

  • Total Body Water: $38\text{--}42\,\text{L}$ (approximately $60\%$ of total body mass).

  • Plasma Compartment (Intravascular): $3\text{--}4\,\text{L}$ (approximately $5\%$ of body weight).

  • Interstitial Fluid Compartment: $12\text{--}14\,\text{L}$ (approximately $16\%$ of body weight).

  • Extracellular Fluid Volume (Plasma + Interstitial): $15\text{--}18\,\text{L}$.

  • Intracellular Fluid Compartment: $25\text{--}28\,\text{L}$ (approximately $35\%$ of body weight).

  • Adipose Fat Compartment: Accounts for approximately $20\%$ of total body weight.

Volume of Distribution ($V_d$)

• Apparent Volume of Distribution ($V_d$) Defined: The theoretical volume of fluid required to contain the total amount of drug present in the body ($Q$) at the same concentration as that measured in blood plasma ($C_p$).

• Mathematical Formula:

$V_d = \frac{Q}{C_p}$

(where $Q$ is the total dose/amount of drug in the body in grams or milligrams, and $C_p$ is the measured plasma concentration in $\text{g/L}$ or $\text{mg/L}$)

• Interpretation of Specific $V_d$ Ranges:

  • $V_d = 3\text{--}4\,\text{L}$: Drug is confined strictly to the vascular plasma space due to large molecular size or high plasma protein binding (e.g., Heparin).

  • $V_d = 12\text{--}14\,\text{L}$: Drug distributes throughout extracellular fluids (plasma and interstitial fluid) but fails to cross cell membranes (e.g., Aspirin).

  • $V_d = 38\text{--}42\,\text{L}$: Drug distributes uniformly throughout total body water (both intracellular and extracellular compartments) (e.g., Phenytoin, Ethanol).

  • $V_d \gg 42\,\text{L}$: Drug extensively binds or sequesters intracellularly within tissue stores, resulting in very low concentrations in blood plasma ($C_p$). Examples include Digoxin ($V_d \approx 500\,\text{L}$) and Imipramine ($V_d \approx 1600\,\text{L}$).

Plasma Protein Binding and Tissue Storage Reservoirs

• Molecular Forms in Blood Circulation:

  • Free Form: Unbound, active, diffusible across cell barriers, available for tissue distribution, biotransformation, and renal excretion.

  • Bound Form: Reversibly attached to plasma transport proteins, biologically inert, non-diffusible, protected from biotransformation and excretion; functions as a circulating drug reservoir.

• Clinical Significance of Binding Interactions:

  • Competitive Displacement: Two drugs with high affinity for the same plasma protein binding sites will compete with one another, leading to displacement interactions.

  • Displacement Example: Nonsteroidal anti-inflammatory drugs (NSAIDs like Phenylbutazone) and salicylates displace Warfarin (an oral anticoagulant) and oral hypoglycemic agents from albumin binding sites. This displacement increases free plasma warfarin levels, creating severe bleeding risks.

  • Pharmacokinetic Impact: Highly plasma protein-bound drugs persist in the body longer (extended half-life), display reduced instantaneous therapeutic activity, distribute less efficiently into tissues, and cannot be effectively removed by hemodialysis during acute poisoning emergency care.

• Major Plasma Binding Proteins:

  • Albumin: The most abundant plasma protein; functions as a multivalent transport depot for neutral, basic, and acidic ligands. Binds $\text{Ca}^{2+}$, $\text{Cu}^{2+}$, $\text{Zn}^{2+}$, bilirubin, uric acid, Vitamin C, adenosine, tetracyclines, chloramphenicol, digitoxin, fatty acids, suramin, quinacrine, penicillin, salicylates, para-aminosalicylate, sulfonamides, streptomycin, acid dyes, phenol red, histamine, triiodothyronine ($\text{T}_3$), thyroxine ($\text{T}_4$), and barbiturates.

  • $\alpha_1\text{-Acid Glycoprotein}$: Binds steroid hormones (transcortin complex), Vitamin B12, sialic acid, and thyroxine.

  • $\alpha_2\text{-Ceruloplasmin}$: Binds $\text{Cu}^{2+}$, lithium carmine, and hemoglobin/haptoglobin complexes.

  • $\beta_1\text{-Transferrin}$: Specific binding transport protein for ferrous iron ($\text{Fe}^{2+}$).

  • $\alpha\text{- and }\beta\text{-Lipoproteins}$: Transport $\text{Zn}^{2+}$, lipids, cholesterol, and fat-soluble vitamins (A, D, E, K).

  • $\gamma\text{-Globulins}$: Immunoglobulins (antibodies).

• Specialized Tissue Storage Reservoirs:

  • Adipose Fat Tissue Storage:

  • Lipophilic, uncharged compounds (e.g., organochlorine pesticides like DDT) rapidly cross cell membranes and sequester in adipose fat tissue.

  • Adipose sequestration lowers the active concentration of the toxicant at target organ sites, serving a protective buffering role.

  • Mobilization Risk: Rapid weight loss or forced starvation triggers rapid lipolysis, mobilizing stored lipophilic toxicants into systemic blood circulation and producing target organ toxicity.

  • Bone Tissue Storage:

  • Toxic heavy metals and mineral ions accumulate in bone tissue (e.g., Fluoride, Lead, Strontium).

  • Approximately $90\%$ of total body lead load ($\text{Pb}$) is localized in the skeletal matrix.

  • Bone-bound toxicants are released continuously back into blood circulation via physiological ion-exchange processes or osteoclast bone resorption.

Specialized Biological Barriers: Blood-Brain Barrier

• Structural Architecture of the Blood-Brain Barrier (BBB):

  • Capillary endothelial cells in brain microvessels are fused continuously by impenetrable tight junctions (zonula occludens), preventing paracellular solute movement between adjacent cells.

  • Glial cell processes (astrocytic end-feet) envelop the outer capillary wall, forming an extra structural sheath.

• Active Efflux Transporter Systems:

  • The luminal (blood-facing) endothelial membrane expresses ATP-dependent active efflux transporters that intercept lipid-soluble xenobiotics crossing into the endothelium and pump them back out into blood circulation.

  • Primary BBB Efflux Transporters: P-glycoprotein (P-gp), Breast Cancer Resistance Protein (BCRP), Multidrug Resistance-associated Proteins 1 and 2 (Mrp1, Mrp2), and Organic Anion Transporting Polypeptide 2 (Oatp2).

• Developmental Susceptibility: The blood-brain barrier is anatomically incomplete and underdeveloped at birth. Consequently, neonates are far more susceptible to central nervous system toxicants (e.g., morphine exhibits 3-fold to 10-fold higher toxicity in newborns than in adults).

• Oncological Implications: Malignant cancer cells frequently overexpress these same active efflux pumps (such as P-glycoprotein and multidrug resistance pumps) following exposure to chemotherapy drugs. The overexpressed pumps export antineoplastic agents out of the tumor cells, causing multidrug resistance.